Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

August 8, 2016

Primary Completion Date

July 18, 2017

Study Completion Date

July 18, 2017

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

Firsocostat

Capsules orally once daily.

DRUG

Placebo

Placebo matched to firsocostat orally once daily.

Trial Locations (36)

10016

New York

15213

Pittsburgh

19707

Philadelphia

22042

Falls Church

23226

Richmond

23249

Richmond

23298

Richmond

27710

Durham

28677

Statesville

30308

Atlanta

33136

Miami

33165

Miami

37211

Nashville

38104

Memphis

38138

Germantown

46202

Indianapolis

55905

Rochester

60611

Chicago

64131

Kansas City

70112

New Orleans

76012

Arlington

78215

San Antonio

78233

Live Oak

84107

Murray

90036

Los Angeles

90048

Los Angeles

92103

San Diego

92118

Coronado

92123

San Diego

92377

Rialto

94115

San Francisco

94143

San Francisco

94404

Foster City

98104

Seattle

99352

Richland

02115

Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY